Patrick Kanouff - 14 Jun 2022 Form 3 Insider Report for Heart Test Laboratories, Inc. (HSCS)

Role
Director
Signature
/s/ Mark Hilz, Attorney-In-Fact
Issuer symbol
HSCS
Transactions as of
14 Jun 2022
Transactions value $
$0
Form type
3
Filing time
06 Jul 2022, 13:41:48 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HSCS Common Stock 7.88K 14 Jun 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HSCS Director Stock Option (Right to Buy) 14 Jun 2022 Common Stock 3.03K $1.29 Direct F1
holding HSCS Director Stock Option (Right to Buy) 14 Jun 2022 Common Stock 1.89K $3.47 Direct F2
holding HSCS Warrants 14 Jun 2022 Common Stock 6.46K $5.16 Direct
holding HSCS Director Stock Option (Right to Buy) 14 Jun 2022 Common Stock 1.89K $3.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
F2 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
F3 The entire option has become fully-vested and may be exercised at any time at the Holder's election.